{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:35:59Z","timestamp":1791336959578,"version":"4.3.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Better understanding of roles of complement in pathology has fuelled an explosion of interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody (mAb) eculizumab, the first of the new wave of complement blocking drugs, was FDA approved for treatment of Paroxysmal Nocturnal Hemoglobinuria in 2007; its expansion into other diseases has been slow and remains restricted to rare and ultra-rare diseases such as atypical hemolytic uremic syndrome. The success of eculizumab has provoked other Pharma to follow this well-trodden track and made C5 blockade the busiest area of complement drug development. C5 blockade inhibits generation of C5a and C5b, the former an anaphylatoxin, the latter the nidus for formation of the pro-inflammatory membrane attack complex. In order to use anti-complement drugs in common complement-driven diseases, more affordable and equally effective therapeutics are needed. To address this, we explored complement inhibition downstream of C5. Novel blocking mAbs targeting C7 and\/or the C5b-7 complex were generated, identified using high throughput functional assays and specificity confirmed by immunochemical assays and surface plasmon resonance (SPR). Selected mAbs were tested in rodents to characterize pharmacokinetics, and therapeutic capacity. Administration of a mouse C7-selective mAb to wildtype mice, or a human C7 specific mAb to C7-deficient mice reconstituted with human C7, completely inhibited serum lytic activity for &amp;gt;48\u00a0h. The C5b-7 complex selective mAb 2H2, most active in rat serum, efficiently inhibited serum lytic activity<jats:italic>in vivo<\/jats:italic>for over a week from a single low dose (10 mg\/kg); this mAb effectively blocked disease and protected muscle endplates from destruction in a rat myasthenia model. Targeting C7 and C7-containing terminal pathway intermediates is an innovative therapeutic approach, allowing lower drug dose and lower product cost, that will facilitate the expansion of complement therapeutics to common diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2020.612402","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T06:56:43Z","timestamp":1607583403000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species"],"prefix":"10.3389","volume":"11","author":[{"given":"Wioleta M.","family":"Zelek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Paul","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.molimm.2018.06.008","article-title":"Developments in anti-complement therapy; from disease to clinical trial","volume":"102","author":"Harris","year":"2018","journal-title":"Mol Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"R\u00f6th","year":"2020","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: First Global Approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019078","article-title":"A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration","volume":"6","author":"Cashman","year":"2011","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199512000-00017","article-title":"Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs","volume":"60","author":"Rollins","year":"1995","journal-title":"Transplantation"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(99)70183-2","article-title":"Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation","volume":"118","author":"Rinder","year":"1999","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.142.8.2654","article-title":"Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6","volume":"142","author":"Biesecker","year":"1989","journal-title":"J\u00a0Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001690","article-title":"Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes","volume":"4","author":"Lin","year":"2020","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2018.07.016","article-title":"Extracting the barbs from complement assays: Identification and optim of a safe substitute for traditional buffers","volume":"223","author":"Zelek","year":"2018","journal-title":"Immunobiology"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1385\/159259056X","volume-title":"Complement Methods and Protocols","author":"Morgan","year":"2000"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13083","article-title":"Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species","volume":"157","author":"Zelek","year":"2019","journal-title":"Immunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13228","article-title":"Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5","volume":"161","author":"Zelek","year":"2020","journal-title":"Immunology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/00325481.1968.11693275","article-title":"Significance of abnormalities of serum complement in human disease","volume":"43","author":"Pickering","year":"1968","journal-title":"Postgrad Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.me.19.020168.000245","article-title":"Complement in human disease","volume":"19","author":"Schur","year":"1968","journal-title":"Annu Rev Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1556\/eujmi.2.2012.2.2","article-title":"The complement system: History, pathways, cascade and inhibitors","volume":"2","author":"Nesargikar","year":"2012","journal-title":"Eur J Microbiol Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2016.06.011","article-title":"Complement research in the 18th\u201321st centuries: Progress comes with new technology","volume":"221","author":"Sim","year":"2016","journal-title":"Immunobiology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1352458519887905","article-title":"Cerebrospinal fluid complement system biomarkers in demyelinating disease","author":"Zelek","year":"2019","journal-title":"Mult Scler J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00362","article-title":"Therapeutic inhibition of the complement system in diseases of the central nervous system","volume":"10","author":"Carpanini","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00281-017-0649-6","article-title":"The eye as a complement dysregulation hotspot","volume":"40","author":"Clark","year":"2018","journal-title":"Semin Immunopathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/imm.12982","article-title":"Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis","volume":"155","author":"Zelek","year":"2018","journal-title":"Immunology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01639","article-title":"Different levels of incomplete terminal pathway inhibition by eculizumab and the clinical response of PNH patients","volume":"10","author":"Harder","year":"2019","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128929","article-title":"Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.152.9.4624","article-title":"Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7","volume":"152","author":"W\u00fcrzner","year":"1994","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1996.d01-663.x","article-title":"How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion","volume":"88","author":"Wurzner","year":"1996","journal-title":"Immunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(89)90139-9","article-title":"A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes","volume":"26","author":"Nam-Ho","year":"1989","journal-title":"Mol Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.18.7123","article-title":"Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: Identity to sulfated glycoprotein 2, a constituent of rat testis fluid","volume":"86","author":"Jenne","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0137630","article-title":"Pseudomonas aeruginosa uses Dihydrolipoamide dehydrogenase (Lpd) to bind to the human terminal pathway regulators vitronectin and clusterin to inhibit terminal pathway complement attack","volume":"10","author":"Hallstr\u00f6m","year":"2015","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2012.02.003","article-title":"Assembly and Regulation of the Membrane Attack Complex Based on Structures of C5b6 and sC5b9","volume":"1","author":"Hadders","year":"2012","journal-title":"Cell Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.01249.x","article-title":"Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes","volume":"103","author":"Fernie-King","year":"2001","journal-title":"Immunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.612402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T22:28:02Z","timestamp":1697322482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.612402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2020.612402"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.612402","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]},"article-number":"612402"}}